Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
3.
Transfus Apher Sci ; 60(3): 103131, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1185295

ABSTRACT

India has almost 3,000 blood centres collecting more than 11 million units annually. Maintaining blood supply during the COVID-19 pandemic is a huge challenge. We conducted a cross-sectional study by an online survey to analyse the variation of practices across blood centers of India during this pandemic. A total of 196 blood centers completely responded to the online survey. Most of the blood centres who responded were part of Government hospitals (60 %), part of an academic institutes (55.6 %) and were directly supporting a COVID hospital (67.5 %). Almost 95.4 % blood centers reported reduction of blood donation mainly due to lockdown (50 %) and inability to conduct camps (17.3 %). Scheduling blood donations was one of the most difficult to implement strategy for maintaining adequate blood donation (40.2 %). Blood center manpower management was also a challenge and upto 48 % blood centers operated in two batches to ensure social distancing in blood banks and reduce the risk of exposure. Hemato-oncology (36.8 %) and obstetrics (33.7 %) were major utilizer of blood during the pandemic. There were marked variations in use of PPE by blood banks staff as well as strategies adopted while conducting immunohematology tests on COVID-19 positive patients samples. This pandemic has highlighted some of the major limitations of the health services but blood services have risen to the challenge and strived to maintain the blood supply chain while ensuring blood donor and staff safety. The wide variations in the practices adopted highlights the need for uniform guidelines for blood services in future pandemics.


Subject(s)
Blood Banks/methods , COVID-19/epidemiology , Blood Banks/organization & administration , Cross-Sectional Studies , Humans , India/epidemiology , Pandemics , SARS-CoV-2/isolation & purification , Surveys and Questionnaires
4.
ISBT Science Series ; n/a(n/a), 2021.
Article in English | Wiley | ID: covidwho-1015570

ABSTRACT

Abstract A 58-day-old female infant reported with complaints of fever, difficult breathing, loose stool, vomiting and refusal to feed for 4 days. Laboratory work showed anaemia, leucocytosis with elevated neutrophils and thrombocytopenia along with high C-reactive protein and D-dimer with bilateral patchy infiltrate on X-ray and positivity for COVID-19. Her blood culture was also positive for Gram-negative bacilli (acinetobacter lwoffii). Along with antibiotics, she was given 50 ml convalescent plasma. She was off oxygen within 2 days and showed improvement in lung lesions, and RT-PCR was negative by day 7 and discharged by day 10 of transfusion.

5.
Transfus Apher Sci ; 60(1): 102956, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-793451

ABSTRACT

The natural history of COVID-19 infection in children is still evolving as the pandemic unfolds. Few cases of severe and often fatal COVID-19 have been reported although the infection is mild in the large majority. Children with cancers are recognised as a high risk group for all infections. Since there aren't any definite treatment guidelines established in children with severe COVID, treatment is guided by adult recommendations which too are often not evidence based. We report the case of a 4-year-old girl with severe COVID-19 associated pneumonia who presented to us as febrile neutropenia. The use of convalescent plasma along with steroids and IVIG showed dramatic results in this child and she recovered without the need for any specific treatment. This is highlighted as one of the earliest cases that is reporting the use of convalescent plasma in a child; the first ever in a child with underlying malignancy.


Subject(s)
COVID-19/therapy , Febrile Neutropenia/therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , COVID-19/etiology , Child, Preschool , Febrile Neutropenia/complications , Female , Humans , Immunization, Passive , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , COVID-19 Serotherapy
SELECTION OF CITATIONS
SEARCH DETAIL